8.2
Nonlinear Pharmacokinetics: Causes of Nonlinearity
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Underst…
Various factors contribute to nonlinearity in drug pharmacokinetics.
Nonlinearity in drug absorption may result from rate-limited solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For example, high doses of propranolol saturate presystemic metabolism, resulting in increased bioavailability.
Nonlinear distribution arises from the saturation of binding sites on plasma proteins or tissues. For instance, a high concentration of phenylbutazone causes a rise in the unbound drug fraction.
Nonlinearity in metabolism stems from capacity-limited metabolism due to enzyme saturation or induction. Repetitive administration of carbamazepine leads to decreased peak plasma concentration through enzyme induction.
Nonlinear renal excretion can occur due to saturation of the tubular carrier system. Saturation can result in increased excretion of glucose and water-soluble vitamins.
Pathological changes also cause nonlinear kinetics. For instance, renal nephrotoxicity from aminoglycosides alters renal drug excretion.
View the full transcript and gain access to JoVE Core videos
Q1: What causes nonlinearity in drug absorption?
Nonlinear drug absorption occurs when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of presystemic metabolism in the gut wall or liver. For example, high doses of propranolol saturate presystemic metabolism, resulting in increased bioavailability. This means small dose changes can produce large variations in plasma concentration.
Q2: How does protein binding saturation affect drug distribution?
Nonlinear distribution arises when binding sites on plasma proteins or tissues become saturated at high drug concentrations. Phenylbutazone exemplifies this: at high concentrations, it saturates plasma protein binding sites, increasing the unbound drug fraction. This pharmacologically active unbound fraction can enhance therapeutic effects or cause potential toxicity.
Q3: What is enzyme autoinduction and how does it affect drug metabolism?
Enzyme autoinduction occurs when repetitive drug administration induces its own metabolism, decreasing peak plasma concentration over time. Carbamazepine demonstrates this phenomenon: repeated doses stimulate enzyme activity, reducing drug levels and potentially affecting efficacy. This nonlinear metabolic process requires dose adjustments to maintain therapeutic effectiveness.
Q4: Why does saturation of renal tubular transporters cause nonlinear excretion?
Nonlinear renal excretion occurs when tubular carrier systems become saturated, reducing the reabsorption of substances like glucose and water-soluble vitamins. When transporters reach saturation capacity, renal clearance of these substances increases. This saturation-dependent mechanism creates dose-dependent changes in drug elimination rates.
Q5: How can pathological changes like nephrotoxicity alter drug pharmacokinetics?
Pathological changes such as renal nephrotoxicity from aminoglycosides directly alter renal drug excretion, causing nonlinear kinetics. Kidney damage impairs the elimination of drugs primarily excreted by the kidneys, leading to drug accumulation and potential toxicity. These pathological effects demonstrate how organ dysfunction disrupts normal pharmacokinetic processes.
Q6: What is the difference between capacity-limited metabolism and enzyme induction?
Capacity-limited metabolism occurs when enzyme saturation limits the rate of drug metabolism at high concentrations, following Michaelis-Menten kinetics. Enzyme induction, conversely, increases enzyme production through repeated drug exposure, enhancing metabolic capacity. Both mechanisms cause nonlinearity but through opposite effects: saturation decreases clearance while induction increases it.
Q7: How do carrier-mediated transport systems contribute to nonlinear absorption?
Carrier-mediated transport systems exhibit saturation kinetics, meaning their transport capacity is limited. When drug concentration exceeds the transporter's capacity, absorption becomes rate-limited, creating nonlinear dose-concentration relationships. This saturable transport mechanism contrasts with passive diffusion and explains why some drugs show disproportionate plasma concentration increases at higher doses.